Drugs / CRISPR/Cas9-HPV16 E6/E7T1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03057912 | Jan → Nov 2018 | human papilloma virus infection | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRISPR/Cas9-HPV16 E6/E7T1 | “CRISPR/Cas9-HPV16 E6/E7T1;CRISPR/Cas9-HPV18 E6/ E7T2” NCT03057912 ↗ |
| Known as | CRISPR/Cas9-HPV18 E6/ E7T2 | “CRISPR/Cas9-HPV16 E6/E7T1;CRISPR/Cas9-HPV18 E6/ E7T2” NCT03057912 ↗ |
| Action | Inhibit | “could produce disruption of HPV16 and HPV18 E6/E7 DNA, significantly decreasing the expression of E6/E7” NCT03057912 ↗ |
| Modality | CRISPR / gene editing | “using designated TALEN and CRISPR/Cas9 as genome editing tool” NCT03057912 ↗ |